kynurenine has been researched along with Lung Neoplasms in 28 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kynurenine synthesis was due to the transcription of the indoleamine 1,2 dioxygenase (IDO) enzyme, consequent to the activation of the signal transducer and activator of transcription-3 (STAT3)." | 5.42 | Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. ( Campia, I; Gazzano, E; Ghigo, D; Kopecka, J; Orecchia, S; Riganti, C; Salaroglio, IC, 2015) |
| "Circulating concentrations of metabolites (collectively called kynurenines) in the kynurenine pathway of tryptophan metabolism increase during inflammation, particularly in response to interferon-gamma (IFN-γ)." | 4.31 | A cross-sectional study of inflammatory markers as determinants of circulating kynurenines in the Lung Cancer Cohort Consortium. ( Arslan, AA; Behndig, AF; Brennan, P; Cai, Q; Chen, C; Chen, Y; Fanidi, A; Freedman, ND; Gaziano, JM; Giles, GG; Huang, WY; Johansson, M; Koh, WP; Langhammer, A; Le Marchand, L; Manjer, J; Meyer, K; Midttun, Ø; Prentice, R; Robbins, HA; Sandsveden, M; Sesso, HD; Shu, XO; Stevens, VL; Sørgjerd, EP; Ueland, PM; Ulvik, A; Visvanathan, K; Wang, Y; Weinstein, SJ; Yuan, JM; Zahed, H; Zhang, X; Zheng, W, 2023) |
| " We investigated the associations for circulating levels of tryptophan, kynurenine, kynurenine:tryptophan ratio (KTR), quinolinic acid (QA) and neopterin as markers of immune regulation and inflammation with lung cancer risk in 5,364 smoking-matched case-control pairs from 20 prospective cohorts included in the international Lung Cancer Cohort Consortium." | 3.96 | Circulating markers of cellular immune activation in prediagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3). ( Albanes, D; Alcala, K; Arslan, AA; Blot, WJ; Brennan, P; Buring, JE; Cai, Q; Caporaso, NE; Fanidi, A; Freedman, ND; Gao, YT; Gaziano, JM; Giles, GG; Grankvist, K; Haiman, CA; Han, J; Hodge, AM; Huang, JY; Hveem, K; Johansson, M; Koh, WP; Lan, Q; Langhammer, A; Larose, TL; Le Marchand, L; Lee, IM; Li, HL; Luu, HN; Manjer, J; Midttun, Ø; Pettinger, M; Prentice, RL; Purdue, MP; Relton, C; Sesso, HD; Severi, G; Shu, XO; Stampfer, MJ; Stevens, VL; Thomson, CA; Ueland, PM; Ulvi, A; Visvanathan, K; Wang, R; Weinstein, SJ; Wilkens, LR; Wu, J; Xiang, YB; Yuan, JM; Zeleniuch-Jacquotte, A; Zhang, X; Zheng, W; Ziegler, RG, 2020) |
| " This study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of LY3381916 monotherapy and in combination with a programmed death-ligand 1 (PD-L1) inhibitor (LY3300054) in patients with advanced solid tumors." | 3.01 | A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. ( Bendell, J; Benhadji, KA; Doman, TN; Galvao, VR; Gandhi, L; Geeganage, S; Jalal, S; Kotecki, N; O'Neil, BH; Prenen, H; Rottey, S; Saha, A; Suriyapperuma, S; Szpurka, AM; Vuagnat, P; Wallin, J; Xia, M; Xu, X, 2021) |
| " Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival." | 1.48 | IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. ( Huang, L; Jin, JY; Jolly, S; Kong, FS; Li, L; Mellor, AL; Pi, W; Wang, W; Wu, H; Yan, L; Zang, Y, 2018) |
| "Treatment of lung cancer is evolving from the use of cytotoxic drugs to drugs that interrupt pathways specific to a malignancy." | 1.48 | Diagnosis of lung tumor types based on metabolomic profiles in lymph node aspirates. ( Bartter, T; Boysen, G; Helms, S; Jeffus, S; Penney, RB; Sappington, D; Siegel, E, 2018) |
| "Kynurenine synthesis was due to the transcription of the indoleamine 1,2 dioxygenase (IDO) enzyme, consequent to the activation of the signal transducer and activator of transcription-3 (STAT3)." | 1.42 | Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. ( Campia, I; Gazzano, E; Ghigo, D; Kopecka, J; Orecchia, S; Riganti, C; Salaroglio, IC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 13 (46.43) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, X | 1 |
| Guo, L | 1 |
| Xing, Z | 1 |
| Shi, L | 1 |
| Liang, H | 1 |
| Li, A | 2 |
| Kuang, C | 1 |
| Tao, B | 1 |
| Yang, Q | 1 |
| Abd El-Fattah, EE | 1 |
| Wu, L | 1 |
| Wang, D | 1 |
| Chen, Y | 2 |
| Qian, M | 1 |
| Xu, X | 2 |
| Zhang, T | 1 |
| Bi, N | 1 |
| Wang, L | 2 |
| Midttun, Ø | 2 |
| Ulvik, A | 1 |
| Meyer, K | 1 |
| Zahed, H | 1 |
| Giles, GG | 2 |
| Manjer, J | 2 |
| Sandsveden, M | 1 |
| Langhammer, A | 2 |
| Sørgjerd, EP | 1 |
| Behndig, AF | 1 |
| Johansson, M | 6 |
| Freedman, ND | 2 |
| Huang, WY | 1 |
| Chen, C | 1 |
| Prentice, R | 1 |
| Stevens, VL | 2 |
| Wang, Y | 2 |
| Le Marchand, L | 2 |
| Weinstein, SJ | 2 |
| Cai, Q | 2 |
| Arslan, AA | 2 |
| Shu, XO | 2 |
| Zheng, W | 2 |
| Yuan, JM | 2 |
| Koh, WP | 2 |
| Visvanathan, K | 2 |
| Sesso, HD | 2 |
| Zhang, X | 3 |
| Gaziano, JM | 2 |
| Fanidi, A | 3 |
| Robbins, HA | 1 |
| Brennan, P | 2 |
| Ueland, PM | 3 |
| Bessede, A | 1 |
| Peyraud, F | 1 |
| Le Moulec, S | 1 |
| Cousin, S | 1 |
| Cabart, M | 1 |
| Chomy, F | 1 |
| Rey, C | 1 |
| Lara, O | 1 |
| Odin, O | 1 |
| Nafia, I | 1 |
| Guegan, JP | 1 |
| Italiano, A | 1 |
| Kober, C | 1 |
| Roewe, J | 1 |
| Schmees, N | 1 |
| Roese, L | 1 |
| Roehn, U | 1 |
| Bader, B | 1 |
| Stoeckigt, D | 1 |
| Prinz, F | 1 |
| Gorjánácz, M | 1 |
| Roider, HG | 1 |
| Olesch, C | 1 |
| Leder, G | 1 |
| Irlbacher, H | 1 |
| Lesche, R | 1 |
| Lefranc, J | 1 |
| Oezcan-Wahlbrink, M | 1 |
| Batra, AS | 1 |
| Elmadany, N | 1 |
| Carretero, R | 1 |
| Sahm, K | 1 |
| Oezen, I | 1 |
| Cichon, F | 1 |
| Baumann, D | 1 |
| Sadik, A | 1 |
| Opitz, CA | 1 |
| Weinmann, H | 1 |
| Hartung, IV | 1 |
| Kreft, B | 1 |
| Offringa, R | 1 |
| Platten, M | 1 |
| Gutcher, I | 1 |
| Nawas, AF | 1 |
| Solmonson, A | 1 |
| Gao, B | 1 |
| DeBerardinis, RJ | 1 |
| Minna, JD | 1 |
| Conacci-Sorrell, M | 1 |
| Mendelson, CR | 1 |
| Nguyen, DJM | 1 |
| Theodoropoulos, G | 1 |
| Li, YY | 1 |
| Wu, C | 1 |
| Sha, W | 1 |
| Feun, LG | 1 |
| Lampidis, TJ | 1 |
| Savaraj, N | 1 |
| Wangpaichitr, M | 1 |
| Xiong, J | 1 |
| Zhang, Y | 2 |
| Wu, B | 1 |
| Fang, L | 1 |
| Wang, N | 1 |
| Yi, H | 1 |
| Chang, N | 1 |
| Chen, L | 1 |
| Zhang, J | 1 |
| Mandarano, M | 1 |
| Orecchini, E | 1 |
| Bellezza, G | 1 |
| Vannucci, J | 1 |
| Ludovini, V | 1 |
| Baglivo, S | 1 |
| Tofanetti, FR | 1 |
| Chiari, R | 1 |
| Loreti, E | 1 |
| Puma, F | 1 |
| Sidoni, A | 1 |
| Belladonna, ML | 1 |
| Kotecki, N | 1 |
| Vuagnat, P | 1 |
| O'Neil, BH | 1 |
| Jalal, S | 1 |
| Rottey, S | 1 |
| Prenen, H | 1 |
| Benhadji, KA | 1 |
| Xia, M | 1 |
| Szpurka, AM | 1 |
| Saha, A | 1 |
| Wallin, J | 1 |
| Suriyapperuma, S | 1 |
| Galvao, VR | 1 |
| Geeganage, S | 1 |
| Doman, TN | 1 |
| Gandhi, L | 1 |
| Bendell, J | 1 |
| Huang, J | 1 |
| Liu, D | 1 |
| Liu, L | 1 |
| Li, J | 1 |
| Yuan, J | 1 |
| Jiang, Z | 2 |
| Hsiao, WW | 1 |
| Liu, H | 1 |
| Khan, I | 1 |
| Xie, Y | 2 |
| Wu, J | 2 |
| Fu, Y | 1 |
| Liao, J | 1 |
| Wang, W | 2 |
| Lai, H | 1 |
| Shi, A | 1 |
| Cai, J | 1 |
| Luo, L | 1 |
| Li, R | 1 |
| Yao, X | 1 |
| Fan, X | 1 |
| Wu, Q | 1 |
| Liu, Z | 1 |
| Yan, P | 1 |
| Lu, J | 2 |
| Yang, M | 1 |
| Cao, Y | 1 |
| Wei, H | 1 |
| Leung, EL | 1 |
| Duan, ZQ | 1 |
| Li, Y | 2 |
| Li, L | 3 |
| Huang, L | 1 |
| Jin, JY | 1 |
| Jolly, S | 1 |
| Zang, Y | 1 |
| Wu, H | 1 |
| Yan, L | 1 |
| Pi, W | 1 |
| Mellor, AL | 1 |
| Kong, FS | 1 |
| Duan, Z | 2 |
| Barsoumian, HB | 1 |
| Schoenhals, JE | 1 |
| Cushman, TR | 1 |
| Caetano, MS | 1 |
| Wang, X | 1 |
| Valdecanas, DR | 1 |
| Niknam, S | 1 |
| Younes, AI | 1 |
| Li, G | 1 |
| Woodward, WA | 1 |
| Cortez, MA | 1 |
| Welsh, JW | 1 |
| Botticelli, A | 1 |
| Cerbelli, B | 1 |
| Lionetto, L | 1 |
| Zizzari, I | 1 |
| Salati, M | 1 |
| Pisano, A | 1 |
| Federica, M | 1 |
| Simmaco, M | 1 |
| Nuti, M | 1 |
| Marchetti, P | 1 |
| Sappington, D | 1 |
| Helms, S | 1 |
| Siegel, E | 1 |
| Penney, RB | 1 |
| Jeffus, S | 1 |
| Bartter, T | 2 |
| Boysen, G | 1 |
| Moon, PK | 1 |
| Tran, S | 1 |
| Minhas, PS | 1 |
| Huang, JY | 1 |
| Larose, TL | 1 |
| Luu, HN | 1 |
| Wang, R | 1 |
| Alcala, K | 1 |
| Albanes, D | 1 |
| Caporaso, NE | 1 |
| Purdue, MP | 1 |
| Ziegler, RG | 1 |
| Lan, Q | 1 |
| Prentice, RL | 1 |
| Pettinger, M | 1 |
| Thomson, CA | 1 |
| Blot, WJ | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Wilkens, LR | 1 |
| Haiman, CA | 1 |
| Stampfer, MJ | 1 |
| Han, J | 1 |
| Hodge, AM | 1 |
| Severi, G | 1 |
| Grankvist, K | 2 |
| Hveem, K | 1 |
| Xiang, YB | 1 |
| Li, HL | 1 |
| Gao, YT | 1 |
| Ulvi, A | 1 |
| Buring, JE | 1 |
| Lee, IM | 1 |
| Relton, C | 2 |
| Iversen, TZ | 1 |
| Engell-Noerregaard, L | 1 |
| Ellebaek, E | 1 |
| Andersen, R | 1 |
| Larsen, SK | 1 |
| Bjoern, J | 1 |
| Zeyher, C | 1 |
| Gouttefangeas, C | 1 |
| Thomsen, BM | 1 |
| Holm, B | 1 |
| Thor Straten, P | 1 |
| Mellemgaard, A | 1 |
| Andersen, MH | 1 |
| Svane, IM | 1 |
| Chuang, SC | 1 |
| Midttun, O | 1 |
| Vollset, SE | 1 |
| Gunter, MJ | 1 |
| Seckl, MJ | 1 |
| Travis, RC | 1 |
| Wareham, N | 1 |
| Trichopoulou, A | 1 |
| Lagiou, P | 1 |
| Trichopoulos, D | 1 |
| Peeters, PH | 1 |
| Bueno-de-Mesquita, HB | 1 |
| Boeing, H | 1 |
| Wientzek, A | 1 |
| Kuehn, T | 1 |
| Kaaks, R | 1 |
| Tumino, R | 1 |
| Agnoli, C | 1 |
| Palli, D | 1 |
| Naccarati, A | 1 |
| Aicua, EA | 1 |
| Sánchez, MJ | 1 |
| Quirós, JR | 1 |
| Chirlaque, MD | 1 |
| Agudo, A | 1 |
| Boutron-Ruault, MC | 1 |
| Clavel-Chapelon, F | 1 |
| Fagherazzi, G | 1 |
| Weiderpass, E | 1 |
| Riboli, E | 1 |
| Brennan, PJ | 1 |
| Vineis, P | 1 |
| Salaroglio, IC | 1 |
| Campia, I | 1 |
| Kopecka, J | 1 |
| Gazzano, E | 1 |
| Orecchia, S | 1 |
| Ghigo, D | 1 |
| Riganti, C | 1 |
| Hsu, YL | 1 |
| Hung, JY | 1 |
| Chiang, SY | 1 |
| Jian, SF | 1 |
| Wu, CY | 1 |
| Lin, YS | 1 |
| Tsai, YM | 1 |
| Chou, SH | 1 |
| Tsai, MJ | 1 |
| Kuo, PL | 1 |
| Suzuki, Y | 1 |
| Suda, T | 1 |
| Furuhashi, K | 1 |
| Suzuki, M | 1 |
| Fujie, M | 1 |
| Hahimoto, D | 1 |
| Nakamura, Y | 1 |
| Inui, N | 1 |
| Nakamura, H | 1 |
| Chida, K | 1 |
| Ehrhart, H | 1 |
| DeGeorge, FV | 1 |
| Brown, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer[NCT03562871] | Phase 1/Phase 2 | 109 participants (Actual) | Interventional | 2018-08-22 | Completed | ||
| IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.[NCT01219348] | Phase 1 | 14 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for kynurenine and Lung Neoplasms
| Article | Year |
|---|---|
IDO/kynurenine pathway in cancer: possible therapeutic approaches.
Topics: Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lung Neoplasms; Male; Tryptophan; | 2022 |
2 trials available for kynurenine and Lung Neoplasms
| Article | Year |
|---|---|
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cel | 2021 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
25 other studies available for kynurenine and Lung Neoplasms
| Article | Year |
|---|---|
IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10.
Topics: ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Carcinoma, Non-Small-Cell Lung; Down- | 2022 |
Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2022 |
A cross-sectional study of inflammatory markers as determinants of circulating kynurenines in the Lung Cancer Cohort Consortium.
Topics: Biomarkers; C-Reactive Protein; Cross-Sectional Studies; Humans; Inflammation; Interferon-gamma; Kyn | 2023 |
Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynuren | 2023 |
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dioxygenases; Head and Neck Neoplasms; Humans; Immunologic | 2023 |
IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells.
Topics: Adenocarcinoma of Lung; B7-H1 Antigen; Humans; Kynurenine; Lung Neoplasms; RNA, Messenger; Tryptopha | 2023 |
Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.
Topics: Adenocarcinoma of Lung; Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Cisplatin; Drug Resistance | 2020 |
Aryl hydrocarbon receptor mediates Jak2/STAT3 signaling for non-small cell lung cancer stem cell maintenance.
Topics: Adult; Aged; Animals; Azo Compounds; Basic Helix-Loop-Helix Transcription Factors; Carcinogenesis; C | 2020 |
Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, | 2021 |
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Deat | 2022 |
Experimental evidences for miR-30b as a negative regulator of FOXO3 upregulated by kynurenine.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Forkhead Box Protein O3; Gene E | 2017 |
IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; C | 2018 |
Promoting epithelial-to-mesenchymal transition by D-kynurenine via activating aryl hydrocarbon receptor.
Topics: Cadherins; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Humans; Kynurenine; Lung Neoplasms; | 2018 |
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Topics: Animals; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, | 2018 |
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Female; Humans | 2018 |
Diagnosis of lung tumor types based on metabolomic profiles in lymph node aspirates.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma, Squamous Cell; Female; Glutathio | 2018 |
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Indoleamine-Py | 2019 |
Involvement of Aryl Hydrocarbon Receptor in L-Kynurenine-Mediated Parathyroid Hormone-Related Peptide Expression.
Topics: Active Transport, Cell Nucleus; Basic Helix-Loop-Helix Transcription Factors; Bone Neoplasms; Cell L | 2019 |
Circulating markers of cellular immune activation in prediagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3).
Topics: Adenocarcinoma of Lung; Adult; Aged; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Squamous C | 2020 |
Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk.
Topics: Adult; Aged; Biomarkers, Tumor; Case-Control Studies; Cohort Studies; Europe; Female; Humans; Kynure | 2014 |
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.
Topics: Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Prol | 2015 |
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis.
Topics: A549 Cells; Animals; Cancer-Associated Fibroblasts; Carcinoma, Lewis Lung; Cell Line, Tumor; Cocultu | 2016 |
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
Topics: Aged; Disease Progression; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lung Ne | 2010 |
[Proceedings: Endogenous carcinogens. Experimental induction of malignant tumors and leukemias by the tryptophan metabolites 3-hydroxyanthranilic acid and 3-hydroxykynurenine].
Topics: 3-Hydroxyanthranilic Acid; Animals; Carcinoma; Kynurenine; Leukemia, Experimental; Lung Neoplasms; M | 1972 |
Differences in tryptophan metabolism between breast cancer patients with and without cancer at other sites.
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Humans; Kynurenic Acid; Kynurenine; Lung | 1970 |